We remain fully committed to supporting the community of patients who rely on the affected devices, and the physicians and customers who are dedicated to meeting patient needs.”
Until we have concluded these discussions, we are not able to publicly provide further details on these responses. “We will work closely with the FDA to clarify and follow up on the inspectional findings and its recent requests related to comprehensive testing. “In connection with the voluntary recall notification in June of this year, the FDA has recently conducted an inspection of a Philips Respironics manufacturing facility in the US,” said Frans van Houten, CEO of Royal Philips. Additionally, the FDA has not changed its recommendation to patients and healthcare providers in relation to affected devices. Importantly, an FDA investigator's list of inspection observations does not constitute a final FDA determination of whether any condition is in violation of the Federal Food, Drug, and Cosmetic Act or any of its implementing regulations. In accordance with normal practice, Philips Respironics will submit its response to the inspectional findings for review by the FDA. On November 12, 2021, the FDA published a list of the observations it provided to Philips Respironics. Following the substantial ramp-up of its production, service, and repair capacity, the repair and replacement program in the US and several other markets is under way.Īs expected, the US Food and Drug Administration (FDA) recently conducted an inspection of a Philips Respironics manufacturing facility in connection with the recall. Amsterdam, the Netherlands – On June 14, 2021, Royal Philips’ (NYSE: PHG, AEX: PHIA) subsidiary, Philips Respironics, initiated a voluntary recall notification* for certain sleep and respiratory care products to address identified potential health risks related to the polyester-based polyurethane (PE-PUR) sound abatement foam in these devices.
0 kommentar(er)
